Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen
Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen is a vaccine.
- First approval
- United States, 2010
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which companies are running trials of Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account